Aethlon Medical Posts $2.06M Q3 Loss, $7M Cash; Oncology Trial Cohort 2 Advances
Aethlon Medical posted a Q3 operating loss of $2.06 million and held $7.0 million cash at December 31, 2025 after a 13.6% expense increase year-on-year. Nine-month operating expenses dropped 26.9% to $5.36 million while Cohort 2 of its Australian oncology trial progressed and its Hemopurifier EV research advanced.
1. Q3 Financial Results
For the quarter ended December 31, 2025, Aethlon Medical recorded an operating loss of $2.06 million, up from $1.81 million a year earlier, driven primarily by a $367,000 increase in payroll and related costs. The Company held approximately $7.0 million in cash at quarter end, with other income of $44,000 from interest on cash balances.
2. Year-to-Date Expense Reduction
During the nine months ended December 31, 2025, consolidated operating expenses declined 26.9% to $5.36 million from $7.34 million a year earlier, reflecting $1.09 million in payroll savings, a $527,000 reduction in general and administrative expenses and $361,000 lower professional fees.
3. Oncology Trial Cohort 2 Progress
Enrollment and treatment of nine-to-18 participants in Cohort 2 of the Australian oncology trial is underway, following Cohort 1 results that showed favorable directional improvements in extracellular vesicle counts, immune cell numbers, safety and tolerability in solid tumor patients on anti-PD-1 therapies.
4. Hemopurifier Research Advancements
The Company’s preclinical EV research platform advanced with Long COVID data published on bioRxiv and submitted for peer review, and under a Material Transfer Agreement, Stavro is evaluating Hemopurifier compatibility with its SLAMB blood treatment system to enable broader clinical application.